SIMIAN RETROVIRUS VACCINE FOR NON-HUMAN PRIMATES

非人灵长类猴逆转录病毒疫苗

• 批准号: 7958652
• 负责人: Preston A Marx
• 金额: $ 6.04万
• 依托单位: TULANE UNIVERSITY OF LOUISIANA
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-05-01 至 2010-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7958652
• 关键词: Acquired Immunodeficiency Syndrome; Animals; Biopsy; Blood; Blood specimen; Body Fluids; California; Computer Retrieval of Information on Scientific Projects Database; Disease; Funding; Gagging; Goals; Grant; Housing; Hybrids; Immunity; Immunization; Immunosuppressive Agents; Infection; Institution; Intestines; Macaca; Macaca mulatta; Monkeys; Pathogenesis; Phase; Primates; Research; Research Personnel; Resources; Retroviridae; Retroviridae Infections; Saliva; Salvia; Serotyping; Simian Retroviruses; Source; Testing; Type D Retrovirus; United States National Institutes of Health; Universities; Vaccines; Vesicular stomatitis Indiana virus; Viremia; Virus; lymph nodes; nonhuman primate; prevent; vaccine candidate

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The goal of this project is to test two candidate vaccines for protection of macaques against Simian Type D Retrovirus (SRV) serotype 2. If successful, this may be helpful in preventing a common spontaneous retrovirus induced immunosuppressive disease in macaques. Infection with SRV-2 is prevalent in wild and has been common in captive macaques and is capable of causing an AIDS like disease in simians. Rapidly spread through body fluids (salvia or blood), SRV-2 can cause an endemic infection of wild and captive macaques colonies. There are currently 8 animals on this study. In phase 1, two animals will be inoculated IV with SRV obtained from in house sources at the Tulane Primate Center. Blood samples, lymph node and intestinal biopsies and saliva were negative for SRV. Another stock of SRV had been obtained from the University of California Davis was used to re-inoculate the 2 monkeys. All post-inoculation SRV infection and pathogenesis were positive for infection by PCR. In phase 2, all animals will be used in vaccine study VSV boosting vaccine strategy. Four rhesus macaques were immunized with VSV-SRV env/gag hybrid viruses. Two additional vaccine negative monkeys and 4 immunized monkeys were challenged intravenously with SRV-2. All control monkeys were positive by PCR for viremia and all 4 immunized monkeys were completely protected. Therefore, VSV-immunization was capable of inducing sterilizing immunity against SRV-2.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 该项目的目的是测试两种候选疫苗，以保护猕猴免受D型D型逆转录病毒（SRV）血清型2。 SRV-2的感染在野外很普遍，在圈式猕猴中很常见，并且能够在邻居中引起艾滋病。 SRV-2迅速通过体液（Salvia或Blood）传播，可能引起野生和圈养猕猴的特有感染。 目前，这项研究有8只动物。 在第1阶段，将通过在图兰灵长类中心的房屋来源获得的SRV接种两只动物。 血液样本，淋巴结和肠活检和唾液为SRV阴性。 SRV的另一批股票是从加利福尼亚大学戴维斯分校获得的，用于重新接种这2只猴子。 所有接种后SRV感染和发病机理均为PCR感染阳性。 在第2阶段，所有动物都将用于疫苗研究VSV促进疫苗策略。 用VSV-SRV Env/GAG杂种病毒对四个恒河猴进行免疫。 SRV-2静脉内对另外两个疫苗负猴和4个免疫猴子进行了挑战。 所有对照猴子均由PCR阳性病毒血症阳性，并且所有4个免疫猴子均受到完全保护。 因此，VSV免疫能够诱导对SRV-2的免疫力进行灭菌。